Roivant Sciences Ltd.

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company dedicated to accelerating the development and commercialization of medicines addressing unmet medical needs across multiple therapeutic areas. The company operates through a distinctive "Vant" model, creating nimble, entrepreneurial subsidiary companies that function as independent biotechnology enterprises while benefiting from centralized capital allocation, shared support functions, and access to proprietary technologies developed at the parent company level.

The company's pipeline includes several late-stage product candidates. Brepocitinib, a JAK1 and TYK2 inhibitor developed through subsidiary Priovant, is under FDA review for dermatomyositis with a target action date in the third quarter of 2026, with additional Phase 3 programs underway in non-infectious uveitis and cutaneous sarcoidosis. IMVT-1402, an FcRn inhibitor developed through subsidiary Immunovant, is in Phase 2/3 development across multiple IgG-mediated autoimmune indications including Graves' disease, rheumatoid arthritis, myasthenia gravis, and Sjögren's disease. Mosliciguat, an inhaled soluble guanylate cyclase activator developed through subsidiary Pulmovant, is in Phase 2 development for pulmonary hypertension associated with interstitial lung disease.

Roivant maintains significant financial resources with consolidated cash, cash equivalents, and marketable securities of approximately $4.3 billion as of March 31, 2026. The company holds ownership stakes in multiple Vants, including 72 percent of Priovant, 56 percent of Immunovant, and 97 percent of Pulmovant on a basic ownership basis. Beyond therapeutics, Roivant incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. The company's website is located at investor.roivant.com. Since its founding in 2014, Roivant has achieved eight FDA approvals and completed fourteen large registrational Phase 3 studies, with twelve yielding positive data.